AU2022216272A1 - Protein m analogs and fusion proteins and their use for inhibiting antibody function - Google Patents

Protein m analogs and fusion proteins and their use for inhibiting antibody function Download PDF

Info

Publication number
AU2022216272A1
AU2022216272A1 AU2022216272A AU2022216272A AU2022216272A1 AU 2022216272 A1 AU2022216272 A1 AU 2022216272A1 AU 2022216272 A AU2022216272 A AU 2022216272A AU 2022216272 A AU2022216272 A AU 2022216272A AU 2022216272 A1 AU2022216272 A1 AU 2022216272A1
Authority
AU
Australia
Prior art keywords
protein
functional fragment
mycoplasma
subject
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022216272A
Other languages
English (en)
Other versions
AU2022216272A9 (en
Inventor
Charles Askew
Brian Kuhlman
Chengwen Li
David Forrest THIEKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of AU2022216272A1 publication Critical patent/AU2022216272A1/en
Publication of AU2022216272A9 publication Critical patent/AU2022216272A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022216272A 2021-02-03 2022-02-03 Protein m analogs and fusion proteins and their use for inhibiting antibody function Pending AU2022216272A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145188P 2021-02-03 2021-02-03
US63/145,188 2021-02-03
PCT/US2022/015127 WO2022169984A1 (en) 2021-02-03 2022-02-03 Protein m analogs and fusion proteins and their use for inhibiting antibody function

Publications (2)

Publication Number Publication Date
AU2022216272A1 true AU2022216272A1 (en) 2023-08-17
AU2022216272A9 AU2022216272A9 (en) 2024-05-02

Family

ID=82741771

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022216272A Pending AU2022216272A1 (en) 2021-02-03 2022-02-03 Protein m analogs and fusion proteins and their use for inhibiting antibody function

Country Status (7)

Country Link
US (1) US20240309055A1 (https=)
EP (1) EP4288445A1 (https=)
JP (1) JP2024505948A (https=)
KR (1) KR20230152008A (https=)
CN (1) CN117203226A (https=)
AU (1) AU2022216272A1 (https=)
WO (1) WO2022169984A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018320849A1 (en) * 2017-08-25 2020-03-05 Ovid Therapeutics Inc. Recombinant adeno-associated vectors
CN112877297A (zh) * 2021-03-27 2021-06-01 哈尔滨元亨生物药业有限公司 一种利用生物反应器制备猫瘟热病毒单克隆抗体的方法
CN115873833B (zh) * 2022-11-08 2024-08-16 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US9593150B2 (en) * 2012-07-16 2017-03-14 The Scripps Research Institute Immunoglobulin-binding human mycoplasma antigens and methods of use thereof
WO2015117057A2 (en) * 2014-01-31 2015-08-06 The Scripps Research Institute Protein m related immunoglobulin-binding polypeptides
KR20220053575A (ko) * 2019-08-01 2022-04-29 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 항체 결합 및 중화 항체 억제를 위한 조성물 및 방법

Also Published As

Publication number Publication date
WO2022169984A1 (en) 2022-08-11
KR20230152008A (ko) 2023-11-02
CN117203226A (zh) 2023-12-08
AU2022216272A9 (en) 2024-05-02
US20240309055A1 (en) 2024-09-19
EP4288445A1 (en) 2023-12-13
JP2024505948A (ja) 2024-02-08

Similar Documents

Publication Publication Date Title
RU2751953C2 (ru) Модифицированные капсидные белки для улучшения доставки парвовирусных векторов
US20240309055A1 (en) Protein m analogs and fusion proteins and their use for inhibiting antibody function
JP2026000908A (ja) 抗体に結合して中和抗体を阻害するための組成物および方法
JP2025121908A (ja) 二重グリカン結合ａａｖ２．５ベクターのための方法および組成物
US20230013145A1 (en) Aav capsid-promoter interactions and cell selective gene expression
US20220347315A1 (en) Methods and compositions for increasing transduction efficiency with cell membrane fusion proteins
US20240271115A1 (en) Methods and compositions for depleting antibodies
US20240238448A1 (en) Use of chemical epigenetic modifiers to modulate gene expression from vectors
US11639509B2 (en) Methods and compositions for dual glycan binding AAV2.5 vector
HK1260937A1 (en) Modified capsid proteins for enhanced delivery of parvovirus vectors
HK1260937B (en) Modified capsid proteins for enhanced delivery of parvovirus vectors

Legal Events

Date Code Title Description
SREP Specification republished